Drug Trial Radar · NCT03600883
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
713
Actual
Start
Aug 27, 2018
Primary completion
May 29, 2026
Study completion May 29, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jul 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Conditions
- KRAS p.G12C Mutant Advanced Solid Tumors
Interventions
sotorasibDrug
Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation
Anti PD-1/L1Drug
Administered as an intravenous (IV) infusion
MidazolamDrug
Administered as an oral hydrochloride (HCI) syrup
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary: Number of subjects with treatment-emergent adverse eventsTime frame: 24 Months
- Primary: Number of subjects with treatment-related adverse eventsTime frame: 24 Months
- Primary: Number of subjects with grade ≥3 treatment-emergent adverse eventsTime frame: 24 Months
- Primary: Number of subjects with serious adverse eventsTime frame: 24 Months
- Primary: Number of subjects with adverse events of interestTime frame: 24 Months
- Primary: Number of subjects with clinically significant changes in vital signsTime frame: Baseline to 24 Months
- Primary: Number of subjects with clinically significant changes in physical examination resultsTime frame: Baseline to 24 Months
- Primary: Number of subjects with clinically significant changes on electrocardiograms (ECGs)Time frame: Baseline to 24 Months
- Primary: Number of subjects with clinically significant changes in clinical laboratory valuesTime frame: Baseline to 24 Months
- Primary: Number of subjects with dose-limiting toxicities (DLTs)Time frame: 21 Days
- Primary: Objective response rate (ORR) as assessed by RECIST 1.1 criteriaTime frame: 24 Months
- Primary: Duration of response (DOR) as assessed by RECIST 1.1 criteriaTime frame: 24 Months
- Primary: Disease control as assessed by RECIST 1.1 criteriaTime frame: 24 Months
- Primary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteriaTime frame: 24 Months
- Primary: Time to response (TTR) as assessed by RECIST 1.1 criteriaTime frame: 24 Months
Locations
133 sites in 16 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
University of California Los Angeles
Los Angeles, California
University of California at SF
San Francisco, California
Sarcoma Oncology Research Center LLC
Santa Monica, California
Rocky Mountain Cancer Centers
Denver, Colorado
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut
Medical Oncology Hematology Consultants Helen F Graham Cancer Center
Newark, Delaware
University of Florida Health
Gainesville, Florida
AdventHealth Orlando Infusion Center
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute
Atlanta, Georgia
Indiana University
Indianapolis, Indiana
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford Health System
Detroit, Michigan
Washington University
St Louis, Missouri
Roswell Park Cancer Institute
Buffalo, New York
Laura and Isaac Perlmutter Cancer Center at New York University Langone
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University Medical Center, Morris Cancer Clinic
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center Cancer Pavillion
Pittsburgh, Pennsylvania
Gibbs Cancer Center and Research Institute - Spartanburg
Spartanburg, South Carolina
Vanderbilt University Ingram Cancer Center
Nashville, Tennessee
Texas Oncology - Austin Central
Austin, Texas
Texas Oncology - Baylor
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
US Oncology Research Investigational Products Center
Fairfax, Virginia
Virginia Cancer Specialists PC
Fairfax, Virginia
Blue Ridge Cancer Care
Salem, Virginia
Seattle Cancer Care Alliance
Seattle, Washington
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.